Discover and read the best of Twitter Threads about #Pennneurology
Most recents (1)
Delighted that the Editorial Board of @NeurologyToday, the news source of the AAN, @AANmember, selected our dendritic cell vaccine trial, led by Dr. Linda Liau, as one of the "Best Advances of 2022." #immunotherapy @PennNeurology @PennNSG @PennCancer
pubmed.ncbi.nlm.nih.gov/36394838/
pubmed.ncbi.nlm.nih.gov/36394838/
The article notes Median OS for 232 patients with nGBM on DCVax = 19.3M from randomization (22.4M from surgery) vs 16.5M from controls; Survival at 48 M = 15.7% vs 9.9%; mOS at 60M, 13.0M vs 5.7%. Survival for 64 patients with rGBM =13.2M vs. 7.8 M, controls. At 24M, 20.7 vs 9.6% 
At 30M, survival was 11.1 vs 5.1% (controls). The study is deemed important because: i) addition of DCVax to SOC resulted in clinically meaningful and statistically significant extension of survival compared to matched, contemporaneous, external controls receiving SOC alone.
